New Platform Identifies Shared Targets for Complex Disease Treatments

Rockefeller University researchers develop PerturbFate to map how genetic mutations converge on regulatory nodes.

Apr. 16, 2026 at 9:19am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in soft blues, greens, and grays, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the complex interplay of genetic factors underlying disease.A new research platform maps how diverse genetic mutations converge on shared regulatory nodes, offering a potential path to develop combination therapies for complex diseases.NYC Today

Researchers at The Rockefeller University have developed a new platform called PerturbFate that can systematically map how different disease-associated genetic variations reshape cells and identify shared regulatory targets. This approach aims to provide a potential strategy for treating complex conditions driven by a wide array of genetic causes, such as cancer and neurodegeneration, by targeting common control points rather than individual mutations.

Why it matters

Complex diseases often arise from hundreds of genetic mutations across diverse pathways, making it difficult for scientists to connect the constellation of mutations to a specific disease outcome or design a single therapy to address them collectively. PerturbFate offers a new way to identify shared regulatory nodes that diverse genetic perturbations funnel into, providing a potential path to develop combination therapies capable of targeting the disease across its many different genetic causes.

The details

PerturbFate allows researchers to observe in real time how different disease-associated genetic variations reshape cells by tracking RNA production, processing, and DNA accessibility within single cells. The goal is to identify regulatory nodes, or common control points, where diverse genetic perturbations converge on the same harmful cell state. Rather than attempting to target every individual mutation, researchers can instead focus on these shared downstream signaling points.

  • The study, titled 'Mapping convergent regulators of melanoma drug resistance by PerturbFate', was published in the journal Nature in April 2026.

The players

The Rockefeller University

A private research university in New York City that has been at the forefront of biomedical research for over a century.

Junyue Cao

Head of the Laboratory of Single-Cell Genomics and Population Dynamics at The Rockefeller University and lead author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“We focus here on cancer drug resistance, but the paper really starts from a broader question: once you know that a disease is associated with hundreds of genes, how do you design one therapy to target it? We wondered whether all these different genes may be mediated by some shared downstream signaling that we can discover and target instead.”

— Junyue Cao, Head of the Laboratory of Single-Cell Genomics and Population Dynamics at The Rockefeller University

What’s next

Following the results in cultured cells, the team plans to transition the PerturbFate approach into living models to investigate the mechanisms of aging and Alzheimer's disease and see if similar regulatory nodes can be identified and targeted in those contexts.

The takeaway

PerturbFate offers a promising new tool to address the challenge of complex diseases driven by a wide array of genetic causes. By mapping how different mutations converge on shared regulatory nodes, researchers can potentially develop combination therapies capable of targeting the disease at its core, rather than treating each individual mutation.